| [1] |
VOS T, LIM S S, ABBAFATI C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204-1222. DOI: 10.1016/s0140-6736(20)30925-9.
|
| [2] |
ONG K L, STAFFORD L K, MCLAUGHLIN S A, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2023, 402(10397): 203-234. DOI: 10.1016/s0140-6736(23)01301-6.
|
| [3] |
|
| [4] |
|
| [5] |
LI Y Z, GUO C X, CAO Y L. Secular incidence trends and effect of population aging on mortality due to type 1 and type 2 diabetes mellitus in China from 1990 to 2019: findings from the Global Burden of Disease Study 2019[J]. BMJ Open Diab Res Care, 2021, 9(2): e002529. DOI: 10.1136/bmjdrc-2021-002529.
|
| [6] |
SENYIGIT A, DURMUS S, GELISGEN R, et al. Oxidative stress and asprosin levels in type 2 diabetic patients with good and poor glycemic control[J]. Biomolecules, 2024, 14(9): 1123. DOI: 10.3390/biom14091123.
|
| [7] |
MUCHUNGUZI A H, KIMARO E, KONJE E T, et al. Factors associated with glycaemic control and diabetes complications in patients at Bugando Medical Centre, Mwanza, Tanzania: a cross-sectional study design[J]. PLoS One, 2024, 19(8): e0308659. DOI: 10.1371/journal.pone.0308659.
|
| [8] |
XING X Y, WANG X Y, FANG X, et al. Glycemic control and its influencing factors in type 2 diabetes patients in Anhui, China[J]. Front Public Health, 2022, 10: 980966. DOI: 10.3389/fpubh.2022.980966.
|
| [9] |
DINAVARI M F, SANAIE S, RASOULI K, et al. Glycemic control and associated factors among type 2 diabetes mellitus patients: a cross-sectional study of Azar cohort population[J]. BMC Endocr Disord, 2023, 23(1): 273. DOI: 10.1186/s12902-023-01515-y.
|
| [10] |
|
| [11] |
中华医学会糖尿病学分会慢性并发症调查组. 1991—2000年全国住院糖尿病患者慢性并发症及相关大血管病变回顾性分析[J]. 中国医学科学院学报, 2002, 24(5):447-451.
|
| [12] |
|
| [13] |
LOWE R N, TRUJILLO J M. Intranasal glucagon: a new way to treat hypoglycemic emergencies[J]. Ann Pharmacother, 2020, 54(8): 780-787. DOI: 10.1177/1060028020905846.
|
| [14] |
DE BOCK M, AGWU J C, DEABREU M, et al. International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: glycemic targets[J]. Horm Res Paediatr, 2024, 97(6): 546-554.
|
| [15] |
BLONDE L, UMPIERREZ G E, REDDY S S, et al. American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update[J]. Endocr Pract, 2022, 28(10): 923-1049. DOI: 10.1016/j.eprac.2022.08.002.
|
| [16] |
ELSAYED N A, ALEPPO G, ARODA V R, et al. 6. glycemic targets: Standards of care in diabetes—2023[J]. Diabetes Care, 2023, 46(Supplement_1): S97-S110. DOI: 10.2337/dc23-s006.
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|